Margaret Kosal, associate professor in the Sam Nunn School of International Affairs was cited in Genetic Engineering & Biotechnology News.
“Sometimes a seemingly innocuous project can take on more malevolent overtones,” Dr. Kosal explains. “For example, a biotech company in southeast Asia decided to engineer a more potent form of the botulinum toxin. From a commercial point of view this makes sense, as less of the product would be needed to have the same effect in cosmetic and medical treatments. Unfortunately, from a biosecurity standpoint, this means the potency of a potential biological weapon increased.”
Read the complete article here.